Seasonal and perennial allergic rhinitis

Active Ingredient: Budesonide

Indication for Budesonide

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Treatment and prevention of signs and symptoms of seasonal and perennial allergic rhinitis.

For this indication, competent medicine agencies globally authorize below treatments:

256 mcg in 2 doses daily

Route of admnistration

Respiratory (Inhalation)

Defined daily dose

256 ug

Dosage regimen

128 ug 2 time(s) per day every day

Detailed description

The dosage should be determined individually. The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. The duration of the therapy with Budesonide nasal spray should be restricted to the period of allergen exposure and depends on the nature and the characteristics of the allergen. For a full therapeutic benefit regular use is essential.

Initial dose

Adults, adolescents and children from 6 years of age

The recommended initial dose of 256 micrograms may be administered once daily in the morning or divided into two administrations, in the morning and in the evening. 2 actuations into each nostril once daily in the morning or 1 actuation into each nostril in the morning and in the evening Children should be treated under guidance of an adult.

Treatment of seasonal allergic rhinitis should be initiated, if possible, before the patient is exposed to allergens. Concomitant therapy may sometimes be necessary to treat the symptoms affecting the eye caused by the allergy.

Maintenance dose

The desired clinical effect appears within about 1-2 weeks. Afterwards, the lowest dose should be chosen that keeps the patient just without symptoms. No better efficacy is to be expected with a dose greater than 256 micrograms.

Active ingredient

Budesonide

Budesonide is a glucocorticosteroid with a high local anti-inflammatory effect. At doses clinically equivalent to systemically acting glucocorticosteroids, budesonide gives significantly less HPA axis suppression and has a lower impact on inflammatory markers.

Read more about Budesonide

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.